Vor Biopharma (NYSE:VOR – Get Rating) had its target price cut by Barclays from $26.00 to $15.00 in a research report report published on Friday morning, The Fly reports. They currently have an overweight rating on the stock.
A number of other brokerages have also recently commented on VOR. Wedbush restated an initiates rating on shares of Vor Biopharma in a research note on Tuesday, July 26th. HC Wainwright dropped their price target on shares of Vor Biopharma from $26.00 to $20.00 and set a buy rating on the stock in a research note on Monday, August 15th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of $22.00.
Vor Biopharma Stock Up 2.9 %
VOR opened at $4.30 on Friday. The stock has a market cap of $163.64 million, a price-to-earnings ratio of -1.86 and a beta of -0.11. The company’s 50-day moving average price is $4.36 and its two-hundred day moving average price is $4.72. Vor Biopharma has a twelve month low of $3.48 and a twelve month high of $18.35.
Institutional Trading of Vor Biopharma
About Vor Biopharma
Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.
- Get a free copy of the StockNews.com research report on Vor Biopharma (VOR)
- Wayfair Still Has Its Fair Share of Issues
- Take Two Interactive Software Stock is Taking One Step Back
- Why did NIO take a $581.11 million loss last quarter?
- This Mid-Cap Tech Stock Embodies Diversified Growth
- Is It Time To Take A Ride With Joby Aviation’s EV Innovations?
Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.